Krystal Biotech reports Q3 2026 results, VYJUVEK revenue up 30%, $400M buyback authorizedNov 2Quarterly updateKrystal Biotech, Inc.
Krystal Biotech registers early-phase trial of KB111 gene therapy for Hailey-Hailey DiseaseJul 21Trial updateKB111Krystal Biotech, Inc.